Kontafarma China Holdings (HKSE:01312) Interest Expense : HK$-15.3 Mil (TTM As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Kontafarma China Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kontafarma China Holdings's interest expense for the six months ended in Dec. 2023 was HK$ -7.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-15.3 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kontafarma China Holdings's Operating Income for the six months ended in Dec. 2023 was HK$ -45.5 Mil. Kontafarma China Holdings's Interest Expense for the six months ended in Dec. 2023 was HK$ -7.0 Mil. Kontafarma China Holdings did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kontafarma China Holdings Interest Expense Historical Data

The historical data trend for Kontafarma China Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kontafarma China Holdings Interest Expense Chart

Kontafarma China Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-20.48

-31.44

-33.61

-23.28

-15.25

Kontafarma China Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial															-16.77	-12.34	-10.94	-8.28	-6.97

Kontafarma China Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-15.3 Mil.

Kontafarma China Holdings (HKSE:01312) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kontafarma China Holdings's Interest Expense for the six months ended in Dec. 2023 was HK$-7.0 Mil. Its Operating Income for the six months ended in Dec. 2023 was HK$-45.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was HK$228.1 Mil.

Kontafarma China Holdings's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Kontafarma China Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Kontafarma China Holdings (HKSE:01312) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kontafarma China Holdings Ltd (HKSE:01312) » Definitions » Interest Expense

Traded in Other Exchanges

N/A

Address

30 Harbour Road, Room 12A 09-20, 12th Floor, Sun Hung Kai Centre, Wanchai, Hong Kong, HKG

Website

https://www.kontafarma.com.hk

Kontafarma China Holdings Ltd is principally engaged in the manufacture and sale of prescription drugs including chemical drugs and traditional Chinese medicine in the PRC, and the operation of fitness centers, provision of fitness and health consulting services, and the operation of franchises. The operating segments include pharmaceutical business and Fitness business. Majority of its revenue derives from pharmaceutical business segment.

Executives

Ning Bo Bao Shui Qu San Jin Guo Tou Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Shan Xi Jiao Tong Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Shan Xi Jian She Tou Zi Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Shan Xi Sheng Ren Min Zheng Fu Guo You Zi Chan Jian Du Guan Li Wei Yuan Hui	2201 Interest of corporation controlled by you
Shan Xi Sheng Gao Su Gong Lu Ji Tuan You Xian Ze Ren Gong Si	2201 Interest of corporation controlled by you
Shan Xi Sheng Guo You Zi Ben Yun Ying You Xian Gong Si Qian Cheng Shan Xi Sheng Guo You Zi Ben Tou Z	2201 Interest of corporation controlled by you
China Health Management Investment Limited	2101 Beneficial owner
Waranty Assets Management (hk) Limited	2201 Interest of corporation controlled by you
Shen Zhen Shi Hua Rong Tai Zi Chan Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Resuccess Investments Limited
Thtf Energy-saving Holdings Limited

Kontafarma China Holdings (HKSE:01312) Headlines

No Headlines